Each year, more than half a million women are diagnosed with cervical cancer and the disease results in more than 300 000 deaths worldwide. Approximately 570 000 cases of cervical cancer and 311 000 deaths from the disease occured in 2018. According to statistics, it accounts for 80% of maglignant tumors in the female reproductive system and is showing a increasing trend of occurence in younger patients. Patients with cervical cancer experience persistent vaginal discharge, and the metastatis of these cancer cells can induce multi-organ disease and infertility. There are various histologic subtypes of cervical cancer, the most common being squamous cell carcinoma (SCC), followed by adenomatous carcinoma (AC). Surgery is currently the mainstream treatment for cervical cancer, however patients with advanced or recurring cervical cancer after often resistent to traditional radiotherapy, and effective treatments are still scarce. Therefore, research on biomarkers and therapeutic targets with predictive value for cervical cancer is particularly important for improving patient survival and prognosis.